Mesoblast

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Bar Reversal

Score

-0.2

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 28 9.9 0.54% 0.94% 7.9% -6.1% 20.5%
SHORT 29 17.6 0.45% 0.76% 5.0% -5.4% -27.0%

Summary

Technical Analysis

Mesoblast (MSB.AX)


Indicator:

BAR REVERSAL


Last Signal:

NEUTRAL


Trading: NO POSITION @ $1.785
Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation but is strengthened by additional indicator confirmation. Indicator can be applied to the short or medium term timeframe and is able to highlight a potential change in price direction. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.


Mesoblast (ASX:MSB)No bar reversal is present for Mesoblast. Over the last 12 months there have been 6 occurrences of no bar reversals giving a signal probability of 2.3%.


PROFILE: Mesoblast (MSB.AX)


Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |

About Mesoblast (ASX:MSB):

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Top 10:

Bar Reversal

Download
Company Close Change(%) Volume Value Signal
BSE BSE 0.24 6.8 118,988 -1 BEARISH
MLD Maca 1.07 5.9 822,651 -1 BEARISH
LOV Lovisa 12.47 4.5 288,055 -1 BEARISH
MND Monadelphous 16.02 4.2 801,429 -1 BEARISH
PPC Peet & Company 1.28 3.7 84,175 -1 BEARISH
LVH Livehire 0.29 3.6 140,281 -1 BEARISH
BLX Beacon Lighting 1.25 2.5 48,849 -1 BEARISH
MAH Macmahon 0.23 2.3 726,723 -1 BEARISH
AQG Alacer Gold Corp 7.25 2.1 274,896 -1 BEARISH
KGN Kogan 7.23 2 366,554 -1 BEARISH